diffuse cutaneous leishmaniasis

dif·fuse cu·ta·ne·ous leish·man·i·a·sis

leishmaniasis caused by several New and Old World species and strains of Leishmania (L. mexicana amazonensis, L. m. pifanoi, possibly L. m. garnhami and L. m. venezuelensis; in Ethiopia, L. aethiopica, and unidentified leishmanial agents in Namibia and Tanzania). The condition is associated with a suppressed cell-mediated immune response, so that the nonulcerating, nonnecrotizing cutaneous lesions can spread widely over the body; great numbers of parasite-filled macrophages are found in the dermal lesions. Healing does not seem to occur unless an acquired cellular hypersensitivity can develop.
See also: cutaneous leishmaniasis.

dif·fuse cu·ta·ne·ous leish·man·i·a·sis

(di-fyūs' kyū-tā'nē-ŭs lēsh'mă-nī'ă-sis)
A disorder caused by several New and Old World species and strains of Leishmania. The condition is associated with a suppressed cell-mediated immune response.
References in periodicals archive ?
Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report.
2001) recorded about 326 cases of human local cutaneous leishmaniasis from 1987 to 1994 in Nayarit (currently a total of approximately 1,200 cases), but in neighboring southern states (Colima and Michoacan) there are almost no reports of cases, except one of diffuse cutaneous leishmaniasis in the Balsas River Basin of Michoacan.
Leishmania (Leishmania) amazonensis is able to produce a wide spectrum of diseases in humans, including localized cutaneous leishmaniasis (LCL), diffuse cutaneous leishmaniasis (DCL), mucocutaneous leishmaniasis (MCL) and VL (Barral et al.
Monocyte suppression of antigen specific responses in diffuse cutaneous leishmaniasis patients Dominican republic.
Diffuse cutaneous leishmaniasis (DCL) resembles leprosy and is difficult to treat.
Infections in humans may either be non-apparent or may display a clinical spectrum ranging from localized, sometimes self-healing cutaneous lesions, to severe mutilating mucocutaneous lesions, or diffuse cutaneous leishmaniasis (AKILOV et al.
More than 2500 patients were treated, including patients with diffuse cutaneous leishmaniasis, mucosal disease and patients co-infected with HIV.
Diffuse cutaneous leishmaniasis produces disseminated and chronic skin lesions resembling those of lepromatous leprosy and is difficult to treat.
Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects.
After promising results were obtained with miltefosine in a patient with anergic diffuse cutaneous leishmaniasis (ADCL) in Venezuela (2), the patient received 150 mg/day oral miltefosine (Impavido, Zentaris, Germany) for 98 days and the lesional parasite load was quantified with quantitative nucleic acid sequence-based amplification (3).

Full browser ?